MAZDU 5mg: The Dual GLP-1/Glucagon Agonist for Weight Loss

MAZDU (Mazdutide) is a GLP-1 and Glucagon receptor co-agonist developed for the management of obesity and metabolic diseases. By combining the anorexigenic action of GLP-1 with the thermogenic effect of Glucagon, it offers a dual approach for fat mass reduction and metabolic health improvement.

How Does MAZDU Work?

Mazdutide activates GLP-1 receptors to reduce appetite and improve insulin sensitivity, while stimulating Glucagon receptors to increase energy expenditure and promote lipolysis. This complementary dual action produces superior results compared to GLP-1 agonists alone.

Scientifically Documented Benefits

Effective Weight Loss

• Significant reduction in body weight
• Appetite suppression and craving reduction
• Accelerated visceral fat mass loss

Increased Energy Expenditure

• Thermogenesis stimulation via glucagon receptors
• Increased basal metabolic rate
• Increased fatty acid oxidation

Metabolic Regulation

• Improved insulin sensitivity
• Better blood sugar control
• Improved lipid profile

Liver Health

• Reduction of non-alcoholic hepatic steatosis
• Improvement of liver enzymes

Recommended Dosage

• Dose: 5mg
• Frequency: 1 injection per week
• Route of administration: subcutaneous injection
• Duration: 12 to 24 weeks depending on goals

Possible Side Effects

• Mild nausea at the start of the protocol
• Transient digestive issues
• Consult a healthcare professional before starting

For laboratory research use only.
Bacteriostatic water required for reconstitution. See our starter kit.